Lupin Limited has announced the completion of its acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a significant step in strengthening its specialty care portfolio and expanding its footprint in Europe.

The acquisition enhances Lupin’s ophthalmology business with a portfolio of over 60 branded products across key therapeutic areas, including dry eye, glaucoma, blepharitis, eyelid hygiene, retinal health, and specialty nutraceuticals.

VISUfarma brings a strong commercial presence across major European markets such as Italy, the UK, Spain, Germany, and France, supported by an experienced team with deep domain expertise and established relationships in the ophthalmology space.

The integration is expected to strengthen Lupin’s ability to address the growing demand for advanced eye care solutions, driven by an ageing population and rising incidence of diabetes-related eye disorders.

“This acquisition marks an important milestone for Lupin, adding a differentiated portfolio of innovative eye health products backed by a well-established commercial infrastructure. It will not only be immediately accretive but also accelerate our specialty growth strategy in Europe,” said Vinita Gupta, CEO, Lupin.

Paolo Cioccetti, CEO Italy, VISUfarma, added, “We are excited to join forces with Lupin. Their global capabilities and commitment to ophthalmology make them an ideal partner to scale VISUfarma’s impact. Together, we aim to advance eye care outcomes across Europe and beyond.”